Summary
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
History
Avinger was founded in 2007 by two leading cardiologists and two Medical Device Veterans. The company’s initial products incorporated the use of Optical Coherence Tomography (OCT)—a technology first used in the 1990s—providing physicians with real-time imaging to quickly and accurately diagnose and treat vessels in the lower leg. After commercially launching its Lightbox family of products in 2012 and Lumivascular products in 2015, Avinger continued to develop and innovate, making advancements and enhancements to OCT imaging technology, and leveraging its experience with catheters and percutaneous technologies.
Mission
Our mission is to provide physicians with technologies that allow them to confidently and accurately treat patients with peripheral artery disease.
Vision
Our vision is to develop and commercialize the world’s most advanced platform of catheter-based, interventional therapies to bring better outcomes to vascular disease patients.
Key Team
Mr. Keith Schaefer (Chief Operating Officer)
Recognition and Awards
Avinger has been recognized for its innovated medical Device with numerous awards including Fierce 15 In MedTech in 2012, Top 14 Medical Device Companies to watch in 2016, and ID Industry Awards 2020 in the micro-innovation category
References
United States 